Technical advances in high-throughput gene sequencing, bioinformatics and cancer immunotherapy now enable the use of the host's immune system to treat cancer. Somatic mutations within the tumor cells give rise to tumor-specific MHC I restricted epitopes or neo-epitopes, that can be recognized by the immune system to differentiate cancer from normal cells. Thus, neo-epitopes make strong candidates for personalized cancer immunotherapy neo-epitope vaccines; whereas generally occurring shared tumor antigens (e.g. KRAS) are candidates for cancer vaccines. Our Clinical Peptides and Pools meet the need for high quality yet fast and affordable peptides for development of individualized therapies*.
Why Work with JPT?
- Two decades worth of experience in peptide drug development and peptide chemistry
- Our algorithms (based on 2.5 million synthesized peptides) rank your neo-epitopes for manufacturability, stability, solubility, hydrophobicity and more
- Our workflows warrant fast turnaround, cost efficiency and success on long peptides
- Regulated according to ISO 9001:2015 standards
JPT’s Clinical Peptides & Pools for GXP product lines are produced in production environments regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy such as peptide vaccines. Depending on the specifics of your immunotherapy protocols, the resulting products are applicable in clinical applications*.
> Further information and quote request: Clinical Peptides
* JPT`s peptides are not produced under GMP and not intended for in vivo use in humans. Any clinical application is subject to local regulatory requirements.